AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 24395436
Drug: 6MP starting
RxNorm normalized name: 2-Amino 6MP
DrugBank: Tioguanine (DB00352)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6MP starting dose <75 mg/m(2)/day in ALL2000 cohort
Trial: 24395436
Drug: 6MP starting
RxNorm normalized name: 2-Amino 6MP
DrugBank: Tioguanine (DB00352)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6MP starting dose 75 mg/m(2)/day in ALL92 cohort
Trial: 21269349
Drug: Triple combination
RxNorm normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple combination (TC) cream and intense pulsed light (IPL)
Trial: 21269349
Drug: Inactive control
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive control cream and intense pulsed light (IPL)
Trial: 9013270
Drug: Enalapril (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (5 mg) + Prazosin (1 mg)
Trial: 1393155
Drug: Tactiling (speechreading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tactiling (speechreading with tactile supplement)
Trial: 18022341
Drug: Regular treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular treatment from GPs
Trial: 16208051
Drug: Carbamazepine (CBZ)
RxNorm normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbamazepine (CBZ) therapy at a dose of 13.1 mg/dL
Trial: 9925135
Drug: 34 g
RxNorm normalized name: Droplet Micron Pen Needles 34 g X 3.5 mm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 34 g conventional soy
Trial: 9925135
Drug: 80 g
RxNorm normalized name: PEG-80 GLYCERYL COCOATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 g conventional soy
Trial: 6794365
Drug: Valproic acid
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valproic acid administered under fasting conditions (250 mg soft-gelatin capsules)
Trial: 6794365
Drug: Valproic acid
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valproic acid administered under nonfasting conditions (250 mg soft-gelatin capsules)
Trial: 6794365
Drug: Valproic acid
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valproic acid administered under nonfasting conditions (250 mg soft-gelatin capsules, excluding one subject who exercised)
Trial: 6794365
Drug: Valproic acid
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valproic acid administered under fasting and nonfasting conditions
Trial: 6794365
Drug: Valproic acid
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valproic acid administered with food
Trial: 21501216
Drug: Atorvastatin (10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (10, 20 or 40 mg day(‐1)) with 300 ml day(‐1) of 100% grapefruit juice for 90 days
Trial: 21501216
Drug: Atorvastatin (50%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (50% reduced dose) with 300 ml day(‐1) of 100% grapefruit juice for 90 days
Trial: 14586484
Drug: Antidepressants (specifics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressants (specifics not provided), often in combination with mood stabilizers
Trial: 10669337
Drug: Hydroxyurea/didanosine combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea/didanosine combination therapy
Trial: 9065377
Drug: Bromfenac sodium
RxNorm normalized name: Bromfenac Sodium
DrugBank: Bromfenac (DB00963)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bromfenac sodium 10 mg
Trial: 9065377
Drug: Bromfenac sodium
RxNorm normalized name: Bromfenac Sodium
DrugBank: Bromfenac (DB00963)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bromfenac sodium 50 mg
Trial: 9065377
Drug: Naproxen sodium
RxNorm normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen sodium 550 mg loading/275 mg repeat doses
Trial: 8380540
Drug: Acyclovir, 400
RxNorm normalized name: Acyclovir, 400 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acyclovir, 400 mg twice daily
Trial: 3549595
Drug: Cyclospasmol 400
RxNorm normalized name: Cyclospasmol 400 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclospasmol 400 mg taken 4 times daily for 12 months
Trial: 3549595
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules taken 4 times daily for 12 months
Trial: 26949762
Drug: Supportive periodontal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive periodontal therapy (SPT) on time for group S1
Trial: 24707373
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg of Estriol as a vaginal cream
Trial: 17533394
Drug: Transperineal biopsy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transperineal biopsy in gray zone PSA (4.1 to 10.0 ng/ml)
Trial: 15534360
Drug: Hyperfractionated radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyperfractionated radiotherapy combined with two cycles of concomitant cisplatin (20 mg/m2 on 5 days of weeks 1 and 5)
Trial: 15534360
Drug: Hyperfractionated radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyperfractionated radiotherapy alone (median dose, 74.4 Gy; 1.2 Gy twice daily)
Trial: 9467542
Drug: MK-677 25
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-677 25 mg daily for 8 weeks
Trial: 2961787
Drug: DHEA 1600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA 1600 mg/day for 28 days
Trial: 28859690
Drug: Staphefekt in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Staphefekt in a cetomacrogol-based cream
Trial: 25673113
Drug: Sodium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium supplementation (3 g d(-1), equals 7.6 g d(-1) of salt)
Trial: 25673113
Drug: Potassium supplementation
RxNorm normalized name: Potassium
DrugBank: Potassium (DB14500)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potassium supplementation (3 g d(-1))
Trial: 23830559
Drug: Mitomycin-C (MMC)
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitomycin-C (MMC) 0.01% (0.1 mg/mL) for 60 seconds
Trial: 23830559
Drug: Mitomycin-C (MMC)
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitomycin-C (MMC) 0.01% (0.1 mg/mL) for 30 seconds
Trial: 23830559
Drug: Mitomycin-C (MMC)
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitomycin-C (MMC) 0.01% (0.1 mg/mL) for 15 seconds
Trial: 21395644
Drug: Neratinib 240
RxNorm normalized name: NERATINIB
DrugBank: Neratinib (DB11828)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Neratinib 240 mg alone
Trial: 21395644
Drug: Neratinib 240
RxNorm normalized name: NERATINIB
DrugBank: Neratinib (DB11828)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Neratinib 240 mg with ketoconazole 400 mg
Trial: 18438103
Drug: DTPa and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTPa and Hib vaccine (mixed prior to administration)
Trial: 18438103
Drug: DTPa and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTPa and Hib vaccine (separate injections)
Trial: 16945613
Drug: Calcium (1
RxNorm normalized name: hydroxyapatite 275 mg calcium (1,100 mg) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium (1 g/day as citrate)
Trial: 9307820
Drug: In vitro
RxNorm normalized name: glucuronidase in vitro test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In vitro measurements with functioning cochlear implant
Trial: 30153236
Drug: Tablet computer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet computer (iPad) with low vision applications and instruction in its use, including accessibility features
Trial: 24262278
Drug: Sofosbuvir (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofosbuvir (400 mg once daily) + Ledipasvir (90 mg once daily) + Ribavirin (RBV) for 12 weeks
Trial: 24262278
Drug: Sofosbuvir +
RxNorm normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sofosbuvir + GS-9669 (500 mg once daily) + Ribavirin (RBV) for 12 weeks
Trial: 20397904
Drug: SRP with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRP with Nd:YAG laser treatment
Trial: 9839827
Drug: Capsaicin cream
RxNorm normalized name: CAPSAICIN 0.1 g in 100 g TOPICAL CREAM [Capsaicin Cream]
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsaicin cream (0.025%)
Trial: 9839827
Drug: GTN cream
RxNorm normalized name: GTN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GTN cream (1.33%)
Trial: 9839827
Drug: GTN cream
RxNorm normalized name: GTN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GTN cream (1.33%) + Capsaicin cream (0.025%)
Trial: 7527418
Drug: Glucose polymer
RxNorm normalized name: glucose polymers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose polymer solution (trial G)
Trial: 27306256
Drug: Individualized physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized physical therapy (10 sessions)
Trial: 25328957
Drug: Integrated cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated cognitive behaviour therapy (CBT) for PTSD and AUD (IT)
Trial: 21556834
Drug: Insulin-stimulated glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin-stimulated glucose uptake in adipose tissue
Trial: 21556834
Drug: Insulin-mediated suppression
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin-mediated suppression of lipolysis and adiponectin metabolism
Trial: 21556834
Drug: Hepatic glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatic glucose metabolism
Trial: 15572462
Drug: IVF treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVF treatment phases (4 distinct stages)
Trial: 10490250
Drug: CharcoAid G
RxNorm normalized name: Activated Charcoal 15 GM Oral Granule [CHARCOAID G]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CharcoAid G (CA)
Trial: 2017645
Drug: Ceftriaxone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (2 g once daily) for 4 weeks
Trial: 2017645
Drug: Ceftriaxone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (2 g once daily for 2 weeks) followed by oral amoxicillin (1 g four times a day for 2 weeks)
Trial: 2017645
Drug: Ceftriaxone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (2 g once daily) for 4 weeks and Ceftriaxone followed by amoxicillin
Trial: 6124760
Drug: Bovine insulin
RxNorm normalized name: Bovine insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bovine insulin
Trial: 25041859
Drug: Weekly adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly adalimumab dosing
Trial: 25041859
Drug: Every other
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Every other week (EOW) adalimumab dosing
Trial: 12536508
Drug: Insulin and
RxNorm normalized name: Isophane insulin and porcine regular insulin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin and hyperosmotic glucose solution
Trial: 12536508
Drug: Moist burn
RxNorm normalized name: Burn Jel Plus
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moist burn ointment (Control)
Trial: 27905102
Drug: Pre-treatment elevated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-treatment elevated HbF
Trial: 26451070
Drug: High-dose vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vitamin D (4000 IU/d)
Trial: 26451070
Drug: Low-dose vitamin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose vitamin D (400 IU/d)
Trial: 21056842
Drug: Chinese herbs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese herbs extra group (CH) with complementary therapies of Chinese medicine and standard treatment
Trial: 21056842
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment only group (ST)
Trial: 17384341
Drug: Individual initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Individual initiation of bedtime insulin glargine
Trial: 17384341
Drug: Group initiation
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group initiation of bedtime insulin glargine
Trial: 7572013
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg buprenorphine (group B)
Trial: 6894099
Drug: tolamolol 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tolamolol 200 mg
Trial: 31806605
Drug: Corticosteroid/alkylating-agent therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid/alkylating-agent therapy
Trial: 15311105
Drug: Troglitazone (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troglitazone (400 mg) and antihypertensive drugs
Trial: 15311105
Drug: Antihypertensive drugs
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive drugs only (Control group)
Trial: 8988115
Drug: Topical 0.2%
RxNorm normalized name: coal tar topical 0.2% topical soap
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.2% GTN ointment
Trial: 30451888
Drug: Mavoglurant (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mavoglurant (up to 100 mg bid for up to 34 months)
Trial: 24920884
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose (fluticasone 1,000 μg + salmeterol 100 μg/day)
Trial: 24920884
Drug: Medium dose
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium dose (fluticasone 500 μg + salmeterol 100 μg/day)
Trial: 18700898
Drug: Parnaparin-MMX (70,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parnaparin-MMX (70, 140, and 210 mg once daily) for 8 weeks
Trial: 8122604
Drug: dl-sotalol 80
RxNorm normalized name: sotalol hydrochloride 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dl-sotalol 80 mg/day
Trial: 8122604
Drug: dl-sotalol 160
RxNorm normalized name: sotalol hydrochloride 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dl-sotalol 160 mg/day
Trial: 8122604
Drug: digoxin monotherapy
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: digoxin monotherapy (placebo)
Trial: 2486654
Drug: Morphine hydrochloride
RxNorm normalized name: Morphine hydrochloride
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine hydrochloride (50 micrograms/kg)
Trial: 700598
Drug: Trospium chloride
RxNorm normalized name: Trospium Chloride
DrugBank: Trospium (DB00209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trospium chloride (oral application)
Trial: 700598
Drug: Trospium chloride
RxNorm normalized name: Trospium Chloride
DrugBank: Trospium (DB00209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trospium chloride (parenteral application)
Trial: 31699751
Drug: Study-approved lotion
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study-approved lotion
Trial: 31699751
Drug: Study-approved cream
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study-approved cream
Trial: 31699751
Drug: Study-approved gel
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study-approved gel
Trial: 31699751
Drug: Study-approved ointment
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study-approved ointment
Trial: 31699751
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care (topical corticosteroids)
Trial: 31699751
Drug: Treatment use
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment use
Trial: 28076735
Drug: Medication management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication management plans completed by a pharmacist (intervention)
Trial: 25817213
Drug: Endodontic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endodontic treatment and scaling and root planning (SRP) performed simultaneously
Trial: 25817213
Drug: SRP performed
RxNorm normalized name: Perform
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRP performed 3 months after endodontic treatment
Trial: 21613350
Drug: 7-h GH
RxNorm normalized name: FUSION PROTEIN OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG- .BETA.)-(118-145)-PEPTIDE (1-28) WITH HUMAN SOMATOTROPIN (GROWTH HORMONE, GH) (29-219) AND TWO TANDEM COPIES OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG-.BETA.)-(118-145)- PEPTIDE (220-247
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-h GH infusion (0.2-0.3 mg in total) that terminated 5 h before the clamp (study 1)
Trial: 21613350
Drug: 7-h GH
RxNorm normalized name: FUSION PROTEIN OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG- .BETA.)-(118-145)-PEPTIDE (1-28) WITH HUMAN SOMATOTROPIN (GROWTH HORMONE, GH) (29-219) AND TWO TANDEM COPIES OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG-.BETA.)-(118-145)- PEPTIDE (220-247
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-h GH infusion timed to continue during the first hour of the clamp (study 2)
Trial: 19357559
Drug: Intravitreal bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal bevacizumab injection after cataract surgery
Trial: 19357559
Drug: Balanced salt
RxNorm normalized name: Balanced Salt Solution
DrugBank: Magnesium chloride (DB09407)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Balanced salt solution injection (Control)
Trial: 11707669
Drug: Tenofovir DF
RxNorm normalized name: LAMIVUDINE 300MG/TENOFOVIR DF 300MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenofovir DF plus Hydroxyurea (500 mg bid for 28 days)
Trial: 11707669
Drug: Tenofovir DF
RxNorm normalized name: LAMIVUDINE 300MG/TENOFOVIR DF 300MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenofovir DF (75 mg once daily for 28 days)
Trial: 3537092
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Theophylline and Albuterol
Trial: 27776678
Drug: PM plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PM plus cognitive behavioral therapy (CBT)
Trial: 23789813
Drug: Bolus saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus saline injection with arm elevation
Trial: 8342756
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no saline injection)
Trial: 16774830
Drug: Intrathecal hyperbaric
RxNorm normalized name: beractant
DrugBank: Beractant (DB06761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal hyperbaric bupivacaine 3.75 mg
Trial: 19843797
Drug: Intrathecal hyperbaric
RxNorm normalized name: beractant
DrugBank: Beractant (DB06761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal hyperbaric bupivacaine 9 mg
Trial: 11206018
Drug: Conservative (ischemia-guided)
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative (ischemia-guided) strategy with aggressive medical therapy
Trial: 11206018
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment (intensive antiplatelet, antithrombotic, and anti-ischemic therapy)
Trial: 8632538
Drug: 1 instillation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 instillation of mitomycin C (40 mg/40 ml water)
Trial: 8632538
Drug: 5 instillations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 instillations of mitomycin C (40 mg/40 ml water)
Trial: 2860183
Drug: Topical povidone-iodine
RxNorm normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical povidone-iodine (PVP-I)
Trial: 20436703
Drug: Tandem high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tandem high-dose chemotherapy and autologous stem cell rescue (HDCT/ASCR)
Trial: 20436703
Drug: Single high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single high-dose chemotherapy and autologous stem cell rescue (HDCT/ASCR)
Trial: 17708780
Drug: Active rTMS
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active rTMS over left dorsolateral prefrontal cortex (DLPFC) (5 Hz rTMS; 120% motor threshold) with placebo pill
Trial: 17708780
Drug: Sham rTMS
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham rTMS with fluoxetine 20 mg/d
Trial: 7104176
Drug: Spironolactone 50
RxNorm normalized name: spironolactone 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone 50 mg daily
Trial: 9431896
Drug: alpha‐IFN 2a,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha‐IFN 2a, 3 MU, three times weekly for 12 months